InsidersTradesSigma
Follow the 케이바이오랩스 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 케이바이오랩스 has recorded 4 insider filings. Market capitalisation: €22.3bn. The latest transaction was disclosed on 2 July 2026 (Other). Among the most active insiders: 미래아이앤지. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
케이바이오랩스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of biopharmaceutical solutions.